标题
Optimal first-line treatment in ovarian cancer
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 23, Issue suppl 10, Pages x118-x127
出版商
Oxford University Press (OUP)
发表日期
2012-09-17
DOI
10.1093/annonc/mds315
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Epithelial Ovarian Cancer
- (2017) Robert J. Morgan et al. Journal of the National Comprehensive Cancer Network
- Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA–IV
- (2012) Stephan Polterauer et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Predictive Value of Symptoms for Ovarian Cancer: Comparison of Symptoms Reported by Questionnaire, Interview, and General Practitioner Notes
- (2012) Anita W. W. Lim et al. JNCI-Journal of the National Cancer Institute
- Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra
- (2011) M. E. L. van der Burg et al. ANNALS OF ONCOLOGY
- Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer
- (2011) J. Alejandro Rauh-Hain et al. ANNALS OF SURGICAL ONCOLOGY
- Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers
- (2011) E-I Braicu et al. BRITISH JOURNAL OF CANCER
- IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer
- (2011) M. S. Anglesio et al. CLINICAL CANCER RESEARCH
- Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types
- (2011) Makiko Higashi et al. GYNECOLOGIC ONCOLOGY
- Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: A meta-analysis
- (2011) Yoo-Young Lee et al. GYNECOLOGIC ONCOLOGY
- Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer
- (2011) Jonathan A. Ledermann et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer
- (2011) Gavin C.E. Stuart et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Effect of Screening on Ovarian Cancer Mortality
- (2011) Saundra S. Buys JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Is the Easier Way Ever the Better Way?
- (2011) Dennis S. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer
- (2011) Jonathan A. Ledermann et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Chemotherapy Is the Better Treatment Option in Some Patients With Stage IIIc to IV Ovarian Cancer
- (2011) Ignace Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
- (2011) Beth Y. Karlan et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
- (2010) Robert J. Kurman et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) N. Colombo et al. ANNALS OF ONCOLOGY
- A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
- (2010) J. J. Biagi et al. ANNALS OF ONCOLOGY
- Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor , in Epithelial Ovarian Cancer: a Phase I Study
- (2010) J. A. Konner et al. CLINICAL CANCER RESEARCH
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
- (2010) Michael Friedlander et al. GYNECOLOGIC ONCOLOGY
- Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer
- (2010) Helen J. Mackay et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
- (2010) Daniela Matei et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
- (2010) Ignace Vergote et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
- (2009) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
- (2009) Noriyuki Katsumata et al. LANCET
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: A systematic review
- (2008) Andreas du Bois et al. GYNECOLOGIC ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started